- Home
- IOVA vs CURB Comparison
IOVA vs CURB Comparison
Compare IOVA & CURB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- CURB
- Stock Information
- Founded
- IOVA 2007
- CURB 2024
- Country
- IOVA United States
- CURB United States
- Employees
- IOVA N/A
- CURB N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- CURB
- Sector
- IOVA Health Care
- CURB
- Exchange
- IOVA Nasdaq
- CURB NYSE
- Market Cap
- IOVA 1.0B
- CURB N/A
- IPO Year
- IOVA N/A
- CURB N/A
- Fundamental
- Price
- IOVA $1.73
- CURB $23.39
- Analyst Decision
- IOVA Strong Buy
- CURB Buy
- Analyst Count
- IOVA 9
- CURB 7
- Target Price
- IOVA $18.22
- CURB $26.29
- AVG Volume (30 Days)
- IOVA 9.3M
- CURB 635.6K
- Earning Date
- IOVA 05-08-2025
- CURB 04-24-2025
- Dividend Yield
- IOVA N/A
- CURB 1.75%
- EPS Growth
- IOVA N/A
- CURB N/A
- EPS
- IOVA N/A
- CURB 0.11
- Revenue
- IOVA $164,070,000.00
- CURB $131,537,000.00
- Revenue This Year
- IOVA $182.20
- CURB $24.92
- Revenue Next Year
- IOVA $62.10
- CURB $16.33
- P/E Ratio
- IOVA N/A
- CURB $212.31
- Revenue Growth
- IOVA 13698.99
- CURB 31.90
- 52 Week Low
- IOVA $2.70
- CURB $18.80
- 52 Week High
- IOVA $13.60
- CURB $25.69
- Technical
- Relative Strength Index (RSI)
- IOVA 24.56
- CURB N/A
- Support Level
- IOVA $3.02
- CURB N/A
- Resistance Level
- IOVA $3.31
- CURB N/A
- Average True Range (ATR)
- IOVA 0.24
- CURB 0.00
- MACD
- IOVA -0.08
- CURB 0.00
- Stochastic Oscillator
- IOVA 6.00
- CURB 0.00
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.